Day One
Take a look at the topics and speakers you can look forward to on day one of this year's 4th Longevity Therapeutics Summit. The agenda has been organized according to the popular hallmarks of aging, preclinical and clinical trials, novel technology in the field and investment opportunities. We have included multiple panel and roundtable discussions to give you an opportunity to ask the speakers questions, have your opinions heard and be a part of crucial debates.
8:00 am
Registration & Morning Coffee
8:50 am Chair’s Opening Remarks
Accelerating the Conversion of Biomarkers of Aging into Registrable Endpoints
9:00 am Can We Save Time in a Bottle?
Synopsis
- Discussing human genetic studies to confirm drug targets
- Exporing biomarkers for longevity therapy
- Considering TAME-paving the road for FDA approval of gerotherapeutics
9:30 am Utilizing Biomarker Assays to Diagnose a Variety of Neurodegenerative Diseases
Synopsis
- Exploring the potential of biomarker assays to revolutionize the diagnostic workup of Alzheimer’s disease
- Assessing the future of relevant biomarkers being discovered in Parkinson’s, general neurodegeneration, and glial activation
- Considering an overview of the latest advancements in the field of biomarkers for neurodegenerative diseases
- Discussing directions regarding implementation of novel biomarkers in clinical practice and trials
10:00 am Molecularizing the Science of Plasma to Therapeutically Target Diseases of Aging
Synopsis
- Discussing an integrated ’omics’ approach to identify protein drivers of health and disease in plasma to therapeutically impact trajectory of aging
- Evaluating the clinical progress in advancing from understanding of the plasma proteome to therapeutics in age-related disorders• Discussing an integrated ’omics’ approach to identify protein drivers of health and disease in plasma to therapeutically impact trajectory of aging
- Evaluating the clinical progress in advancing from understanding of the plasma proteome to therapeutics in age-related disorders
10:30 am
Structured Networking Break
Synopsis
This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the longevity field and establish meaningful business relationships to pursue for the rest of the conference.
11:30 am Panel Discussion: The Lack of Robust Surrogate Biomarkers for Aging
Synopsis
Join keynote speakers as they discuss the lack of robust biomarkers in the longevity field and methods to overcome this including:
- Evaluating novel biomarkers that may correlate to registrable endpoints in longevity therapeutics
- Assessing how to move novel biomarkers towards regulatory approval
- Discussing the importance of developing defined biomarkers for aging and how we can use robust biomarkers to move the longevity field forward
The Rise of Senolytics: What is the Future of Cell Senescence in Longevity Therapeutics?
12:00 pm Highlighting Senescence-Derived Biomarkers of Aging & Osteoarthritis
Synopsis
- Discussing the development of panels of proteins which serve as markers for aging phenotypes in order to monitor potential therapeutic interventions
- Zooming in on senescence-derived biomarkers of aging
- Assessing senescence markers in cartilage and bone targeting underlying mechanisms and options for intervention for osteoarthritis
12:30 pm Harnessing Endogenous Immune Biology to Ablate Pathogenic Senescent Cells & Treat Disease
Synopsis
- Discussing therapeutically harnessing the immune system to remove senescent cells in a disease state
- Achieving therapeutically relevant endpoints and durable effects
- Outlining how there has been a paradigm shift for systemically treating age related multi-morbidities
1:00 pm
Lunch & Networking
2:00 pm Get Your Signals Straight: Extending Healthspan with NaNots Against Pathogenic Signals & Inhibitors
Synopsis
- The Signalome & role in disease & aging
- What are NaNots?
- Targeting soluble immune inhibitors as senolytics (FDA disease is cancer – targets are the same)
- Targeting inflammatory cytokines to treat “Inflamm-aging” (FDA disease is sepsis – targets are the same)
- Ultimate vision of NaNots as “signal tweakers” for maintaining health
2:30 pm Computational Discovery of Cellular Senescence in Age-Related Diseases to Develop Selective Senolytics
Synopsis
- Discussing the definition of senescent cells as heterogeneous cell populations and considering that not all senescent cells are pathological cells
- Assessing bioinformatic strategies that enable the discovery of senescent cell types to target in specific age-related diseases
- Examining the development of selective novel classes of senolytics for effective pharmacological strategies to treat age-related diseases
3:00 pm Roundtable Discussion: An Evaluation of the Rise of Senolytics & the Future of Targeting Senolytic Cells
Synopsis
Join your session leaders in this roundtable as they spark conversation on:
- The sudden rise in targeting senescent cells
- Novel clinical and preclinical trials that are progressing in the senescent space
- Discussing whether research should be focus solely on cellular senescence or take a cocktail approach alongside other hallmarks of aging
3:30 pm
Poster Networking Session
Synopsis
Join your peers to discover the latest developments and breakthroughs, grow your network of meaningful industry connections and showcase your work to colleagues in the longevity field.
Turning Back Time with an Epigenetic Clock & Novel Preclinical & Clinical Trials that are Promoting Regeneration
4:00 pm Can Rapamycin Safely Delay or Reverse Aging Outside the Lab?
Synopsis
- Discussing how Rapamycin is the most effective and reproducible drug for increasing lifespan and healthspan metrics in laboratory animals
- Analyzing anecdotal data from people taking low dose rapamycin is suggestive of benefits for healthspan
- The effects of rapamycin on age-related indications are beginning to be tested in randomized clinical trials
4:30 pm Discussing the Ability to Use Epigenetic Programming to Reverse Aging
Synopsis
- Analyzing evidence that shows epigenetic reprogramming can reverse aging in cells
- Discussing methods of partial epigenetic reprogramming and evaluating the major challenges
- Assessing the hypotheses that it is possible to separate the cell identity from the cell age and the implications this would have on epigenetic programming
5:00 pm Developing Pluripotent Stem Cell-Based Therapies for the Treatment of Age-Related Diseases
Synopsis
- Examining how pluripotent stem cells (PSCs) are a key starting material for the development of off-the-shelf cell-based therapies to help treat patients with high unmet medical needs
- Outlining the key challenges in the value chain of PSC-based therapies and discussing strategies to overcome these challenges
- Analyzing how overcoming immunogenicity will help improve and expand the clinical application of allogeneic PSC-based therapies
- Discussing how the marriage of gene editing technologies with PSC technology is helping to create the next generation of engineered cell therapies that go above and beyond what naturally occurring cells of a patient’s body can do
5:30 pm Exploiting Large Scale Human Genetics Data to Advance Pharmaceutical Research in Aging Related Diseases
Synopsis
- Through a public-private partnership, we have successfully generated whole genome sequence on all 500,000 samples from volunteers in the UK Biobank
- Linked with rich phenotype data collected on these individuals, we have the capability to enable better understanding of the biology of aging related diseases
- We will outline our efforts to develop and deploy computational infrastructure and data science capabilities to translate this massive data set into pharmacological insights
- We encourage engagement with academic and industry partners to facilitate and advance our therapeutic strategy to discover and deliver safe and effective medicines in
this space
6:00 pm Using Recombinant Protein GDF11 to Promote Recovery Post Stroke
Synopsis
- Exploring how GDF11 plays an important role in aging, regeneration and repair
- Analyzing evidence that recombinant GDF11 (rGDF11) promotes recovery post stroke
- Discussing why Elevian is sponsoring rGDF11 clinical trials to promote recovery from stroke and other aging-associated diseases
6:30 pm Examining Anti-Aging Therapies Targeting Endogenous “Retrobiome” & Immunosenescence
Synopsis
- Discussing how aging is associated with genetic and epigenetic modulations of somatic cells accompanied with progressive immunosenescence
- Assessing new insights into the intrinsic mechanisms of DNA damage, agerelated inflammation and immunosenescence
- Examining approaches to their therapeutic correction with small molecules targeting LINE-1 retrotransposons and immunomodulators will be presented
7:00 pm
Chair’s Closing Remarks & End of Day One
